CurrentCentenePolicy CP.MP.150

Phototherapy for Neonatal Hyperbilirubinemia (PDF)

Defines medical necessity criteria for conventional LED-based home phototherapy for neonatal hyperbilirubinemia and states inpatient phototherapy/exchange transfusion are medically necessary when national decision support tools indicate. Provides exclusion risk factors and acceptable total serum bilirubin (TSB) thresholds by postnatal age for home phototherapy.

Policy Summary

PayerCentene

PolicyPhototherapy for Neonatal Hyperbilirubinemia (PDF)

Policy CodePolicy CP.MP.150

Change TypeAnnual review; mixed revisions and clarifications

Effective Date

Next Review Date

Key ActionIf seeking inpatient phototherapy despite meeting home phototherapy criteria, provide documentation of extenuating circumstances to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

Updated Criteria I.J.1. wording from 'glucose-6-phosphate dehydrogenase (G6PD)' to 'G6PD deficiency' on 06/25 approval.

Rearranged verbiage regarding infants ≥ 38 weeks gestation and removed 'Term' verbiage (08/24 approval).

Clarified that inpatient phototherapy is not medically necessary when home criteria are met unless extenuating circumstances documented; added note about admission if TSB >1 mg/dL above AAP threshold (multiple revisions in 10/21 and 10/22).

Added explicit list of 17 risk/exclusion factors for home phototherapy (across revisions 10/21 onward).

Defined acceptable TSB thresholds for home phototherapy by age (Table 1).

17Listed risk/exclusion factors for home phototherapy

TSB age ranges in Table 1

2CPT/HCPCS codes referenced

CP.MP.150Policy Reference Number

Coverage Summary

This policy defines medical necessity for conventional LED-based home phototherapy for neonatal hyperbilirubinemia and specifies that inpatient phototherapy or exchange transfusion are medically necessary when indicated by current nationally recognized decision support tools. It applies to infants meeting all home phototherapy criteria including gestational age ≥ 38 weeks, postnatal age ≥ 48 hours, availability of an LED-based blue-green phototherapy device (460–490 nm) in the home, daily TSB measurement, and no prior phototherapy. The policy lists exclusion risk factors that preclude home phototherapy (e.g., isoimmune hemolytic disease, G6PD deficiency, HIE/asphyxia, sepsis, temperature instability, albumin < 3.0 g/dL, birth weight < 2500 g, significant cephalohematoma/bruising, weight loss ≥ 10%, jaundice in first 24 hours, Down syndrome, macrosomic infant of a diabetic mother, etc.) and states that inpatient care (including exchange transfusion) is medically necessary when national decision tools indicate.

ref

b0_0

text_missing_description_or_field_error

Key thresholds and quick facts

Gestational age thresholdInfant is ≥ 38 weeks gestation

Postnatal age for home therapyInfant ≥ 48 hours old

Albumin exclusionAlbumin < 3.0 g/dL (if measured) excludes home phototherapy

Birth weight exclusionBirth weight < 2500 g excludes home phototherapy

Weight loss exclusionWeight loss ≥ 10% excludes home phototherapy

AAP inpatient admission triggerAdmit if TSB > AAP phototherapy threshold + 1 mg/dL

Policy reference & statusPolicy Reference Number CP.MP.150 — STATUS: CURRENT

Medical Necessity Criteria

Inpatient Phototherapy - When Not Medically Necessary vs Necessary

Policy statements regarding inpatient phototherapy when home phototherapy criteria are met or not met:

ALL of the following

When criteria for home phototherapy are met, inpatient phototherapy for hyperbilirubinemia is not medically necessary unless documentation of extenuating circumstances (including, but not limited to, expected lack of ability to adhere to therapy at home) is provided
Infants should be admitted for inpatient phototherapy if the TSB concentration is more than 1 mg/dL above the AAP guidelines phototherapy treatment threshold (per bili risk tool)TSB > AAP threshold + 1 mg/dL
Other treatment for hyperbilirubinemia, including inpatient phototherapy when not meeting criteria for home phototherapy and exchange transfusion, is medically necessary when meeting the most current version of the relevant nationally recognized decision support tools

Not Covered / Experimental Considerations

Coverage stance: Mixed — home phototherapy is conditionally covered when all specified criteria are met. Home phototherapy is not appropriate and should not be used when any of the listed risk/exclusion factors are present (the policy enumerates 17 such factors). When the home criteria are met, inpatient phototherapy for hyperbilirubinemia is not medically necessary unless there is documentation of extenuating circumstances (for example, expected inability to adhere to therapy at home). Infants should be admitted for inpatient phototherapy if the TSB concentration is more than 1 mg/dL above the AAP guideline phototherapy treatment threshold per the bili risk tool; other inpatient phototherapy and exchange transfusion are medically necessary when meeting current nationally recognized decision support tools.

ref

b2_0

text_missing_description_or_field_error

Codes

Phototherapy / Home phototherapy codes referencedHCPCS|CPT

E0202	Phototherapy (bilirubin) light with photometer
S9098	Home visit, phototherapy services (e.g., Bili-lite), including equipment rental, nursing services, blood draw, supplies, and other services, per diem

Provider Actions and Billing Guidance

Prior Authorization

Documentation for inpatient phototherapy when home criteria met

When requesting inpatient phototherapy for an infant who otherwise meets criteria for home phototherapy, provide documentation of extenuating circumstances (for example, expected inability to adhere to therapy at home) to support medical necessity for inpatient admission.

Documentation Required

Daily TSB monitoring for home phototherapy

Total serum bilirubin (TSB) must be measured daily while the infant is receiving home phototherapy and those daily TSB measurements should be documented in the medical record.

Background and Evidence

Background: Screening and management of neonatal hyperbilirubinemia aim to prevent bilirubin-induced neurologic dysfunction and kernicterus; universal screening prior to discharge is recommended. The 2022 AAP clinical practice guideline updated recommendations for assessment and treatment of infants ≥ 35 weeks, including consideration of home phototherapy. Phototherapy is the first-line treatment—preferably intensive blue-green (460–490 nm) LED phototherapy at recommended irradiance—and can be delivered in the hospital or at home for appropriate, otherwise healthy term infants without hemolysis or other risk factors.

ref

b5_0

text_missing_description_or_field_error

Evidence

Unsupported block type: paragraph

Definitions

Unsupported block type: definition

Revision History

06/25revised (non-material)Latest

Updated Criteria I.J.1. wording from 'glucose-6-phosphate dehydrogenase (G6PD)' to 'G6PD deficiency' on 06/25 approval. Annual review; coding and descriptions reviewed; background updated with no impact to criteria; reviewed by external specialist.

08/24revised (non-material)

Rearranged verbiage regarding infants ≥ 38 weeks gestation and removed 'Term' verbiage (08/24 approval). Annual review; no impact to coverage criteria.

10/21revised (material)

Policy Summary

PayerCentene

PolicyPhototherapy for Neonatal Hyperbilirubinemia (PDF)

Policy CodePolicy CP.MP.150

Change TypeAnnual review; mixed revisions and clarifications

Effective Date

Next Review Date

Key ActionIf seeking inpatient phototherapy despite meeting home phototherapy criteria, provide documentation of extenuating circumstances to support medical necessity.

SourceLink

On This Page

Documentation Required

Follow-up and provider availability

Confirm and document that a primary care provider is willing to manage the infant's home care and that follow-up is arranged within 12 to 24 hours after discharge; include the planned follow-up timeframe and responsible provider in the record.

Billing Rule

Use of phototherapy codes

Report appropriate phototherapy equipment and home service codes per coding guidance. Inclusion of codes does not ensure coverage; follow applicable plan- and state-specific rules.

E0202
S9098

Denial Risk

Exclusion risk factors will preclude home phototherapy

Home phototherapy is contraindicated when any of the policy-listed risk factors are present; the presence of such exclusions may lead to denial of home phototherapy.

Isoimmune hemolytic disease (positive direct antiglobulin test), G6PD deficiency, or other hemolytic disease
Hypoxic Ischemic Encephalopathy (HIE)/Asphyxia
Sepsis
Temperature instability
Birth weight < 2500 g
Significant cephalohematoma or bruising
Jaundice appearing in the first 24 hours of life
Albumin < 3.0 g/dL (if measured)
Weight loss ≥ 10%

10/22revised (material)

10/22added (material)

Added explicit list of 17 risk/exclusion factors for home phototherapy (across revisions 10/21 onward), including G6PD deficiency, HIE, sepsis, albumin <3.0 g/dL, birth weight <2500 g, weight loss ≥10%, jaundice in first 24 hours, Down syndrome, macrosomic infant of diabetic mother, and others.

10/21added (material)

Defined acceptable TSB thresholds for home phototherapy by age (Table 1): 24–36 h ≤11 mg/dL; 36–48 h ≤14 mg/dL; 48–60 h ≤15 mg/dL; 60–72 h ≤16 mg/dL; >72 h ≤17 mg/dL.